The Young Investigator Award (YIA) provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this award is to fund physicians during the transition from a fellowship program to a faculty appointment.
Young Investigator Award supporters and donors: Abbott Oncology
Amgen (2)
ASCO and The ASCO Cancer Foundation Board of Directors
ASCO Clinical Practice Committee
AstraZeneca
Boehringer Ingelheim Pharmaceuticals, Inc.
Bristol-Myers Squibb
The Breast Cancer Research Foundation
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany
Estate of Sandr Syms (2)
Genentech BioOncology™ (5)
Journal of Clinical Oncology
Kidney Cancer Association
Merck Oncology
Millennium: The Takeda Oncology Group
Novartis Oncology (4)
OSI Pharmaceuticals, Inc.
Pfizer Oncology
Roche (5)
sanofi-aventis U.S. (3)
Sarcoma Foundation of America
WWWW Foundation, Inc. (Quad W) )
The total award amount is $50,000 payable on July 1 and January 1 in two equal installments. The number of YIA grants in each funding cycle is not predetermined by The ASCO Cancer Foundation. Awards are given based on individual merit and availability of funds.
The budget guidelines are as follows:
Research support: At least $46,000 should support costs directly related to the research project such as personnel salary, supplies, equipment, and other expenses. Patient care costs that are reimbursable by a third-party payor are unallowable costs.
Travel: Up to $1,500 should be allotted specifically for the applicant's travel to the annual meeting and for any other travel essential to conducting the study. Attendance is mandatory at the ASCO Annual Meeting upon acceptance of the grant.
Indirect costs: Up to $2,500 (or 5% of the yearly total award amount) can be applied to overhead or facilities and administrative costs of the recipient's institution in administering the recipient's research project.
The Young Investigator Award is intended to support proposals with a clinical research focus. ASCO's definition of clinical research is "hypothesis-driven research that employs measurements in whole patients of normal human subjects, in conjunction with laboratory measurements as appropriate, on the subjects of clinical biology, natural history, prevention, screening, diagnosis, therapy, or epidemiology of neoplastic disease" (Journal of Clinical Oncology, Vol. 14, No. 2, 1996 pp. 666-670). In Young Investigator Award proposals, preclinical in vitro and/or animal studies are acceptable as long as the outcome of these studies would ultimately lead to patient-oriented clinical research.
The applicant must meet the following criteria:
Be a physician (MD, DO, or international equivalent with explanation) who is currently in the last two years of his/her final subspecialty training at an academic medical institution at the time of grant submission.
An institutional commitment for a faculty appointment at the time of grant submission is not required, but the applicant should be working in an oncology laboratory or clinical research setting
Have a mentor in the proposed research field from the sponsoring institution. The mentor must assume responsibility and provide guidance for the research. If the mentor is not an active ASCO member, a supporting letter from an active ASCO member must be included.
Be planning an investigative career in clinical oncology
Be a member of ASCO or have submitted a membership application with the grant application
Be able to commit at least 60% of full-time effort in research (applies to total research, not just the proposed project) during the award period.
An MD, PhD is eligible if the terminal degree is completed prior to the start of the grant period. For foreign-trained physicians, equivalency will be determined on a case by case basis.
Eligible physicians may submit only one application to The ASCO Cancer Foundation per year
The ASCO Cancer Foundation Grants Selection Committee reserves the right to evaluate and determine applicants’ eligibility based on the information and justifications included in the application materials.
Full Application Due: September 9, 2009 by 5 pm EDT
Notification: April 2010
Award Term: July 1, 2010 - June 30, 2011
Applicants are encouraged to start their application early due to the complexity of the online application process.
Full Application
All applications must be submitted in accordance with the requirements and instructions of the Request for Proposals (RFP). All application materials must be in English and must be submitted online. No paper applications will be accepted.
The full application must be submitted by 5:00pm EDT on September 9, 2009.
Mandatory Components
Contact Information
Project Information (includes Abstract, IRB, and Animal Use Assurances)
The online application will open on July 1, 2009. Please return to this site at that time for the most current application requirements and to initiate your application.
The ASCO Cancer Foundation Grants Selection Committee will select the recipient based on the following criteria:
Significance and originality of the proposed study and hypothesis
Appropriateness, feasibility, and adequacy of the proposed experiment and methodology
A focus on patient-oriented and, ultimately, clinical research
The qualifications and experiences of the applicant. Factors considered include the quality and extent of past education, scientific training, research experience, research originality, productivity, potential for independent investigation, and commitment to a career in clinical oncology research.
Availability of institutional resources to support the proposed project
Quality of the mentor and the plan for mentor interactions with the applicant